Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Rating of “Moderate Buy” by Analysts

Revolution Medicines, Inc. (NASDAQ:RVMD) has received a consensus rating of “Moderate Buy” from the twenty-two analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $144.00.

RVMD has been the topic of several recent research reports. Stifel Nicolaus restated a “buy” rating on shares of Revolution Medicines in a research report on Monday, April 20th. Needham & Company LLC lifted their price target on Revolution Medicines from $183.00 to $235.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Wedbush boosted their price objective on Revolution Medicines from $165.00 to $181.00 and gave the company an “outperform” rating in a research note on Thursday, July 2nd. Truist Financial increased their price objective on Revolution Medicines from $179.00 to $210.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a research note on Tuesday, April 21st.

Insider Transactions at Revolution Medicines

In related news, Director Sushil Patel sold 5,580 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $187.99, for a total transaction of $1,048,984.20. Following the completion of the transaction, the director directly owned 21,656 shares in the company, valued at $4,071,111.44. The trade was a 20.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Stephen Michael Kelsey sold 4,175 shares of the company’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $156.12, for a total value of $651,801.00. Following the completion of the transaction, the insider owned 291,876 shares in the company, valued at $45,567,681.12. This represents a 1.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 252,497 shares of company stock valued at $39,481,286. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of Revolution Medicines by 6.7% in the 4th quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company’s stock valued at $1,331,739,000 after purchasing an additional 1,056,792 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Revolution Medicines by 194.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,289 shares of the company’s stock worth $1,696,000 after purchasing an additional 14,062 shares during the period. Mass General Brigham Inc bought a new stake in Revolution Medicines in the fourth quarter worth $27,407,000. Eagle Health Investments LP bought a new stake in Revolution Medicines in the fourth quarter worth $9,231,000. Finally, M&T Bank Corp purchased a new stake in Revolution Medicines during the fourth quarter valued at about $52,723,000. 94.34% of the stock is currently owned by institutional investors.

Revolution Medicines Stock Performance

NASDAQ RVMD opened at $186.88 on Monday. The company’s 50 day moving average is $161.23 and its 200-day moving average is $124.78. Revolution Medicines has a 12-month low of $34.00 and a 12-month high of $193.82. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.19. The firm has a market cap of $39.73 billion, a P/E ratio of -26.43 and a beta of 1.37.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($2.29) EPS for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same period in the prior year, the company earned ($1.13) EPS. Sell-side analysts predict that Revolution Medicines will post -7.92 earnings per share for the current year.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.